PH12013500675B1 - Stable and soluble antibodies - Google Patents

Stable and soluble antibodies

Info

Publication number
PH12013500675B1
PH12013500675B1 PH1/2013/500675A PH12013500675A PH12013500675B1 PH 12013500675 B1 PH12013500675 B1 PH 12013500675B1 PH 12013500675 A PH12013500675 A PH 12013500675A PH 12013500675 B1 PH12013500675 B1 PH 12013500675B1
Authority
PH
Philippines
Prior art keywords
antibodies
tnf
methods
stable
provides
Prior art date
Application number
PH1/2013/500675A
Other languages
English (en)
Other versions
PH12013500675A1 (en:Method
Inventor
Leonardo Borras
David Urech
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44897558&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH12013500675(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PH12013500675A1 publication Critical patent/PH12013500675A1/en
Publication of PH12013500675B1 publication Critical patent/PH12013500675B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
PH1/2013/500675A 2010-10-22 2011-10-24 Stable and soluble antibodies PH12013500675B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40579810P 2010-10-22 2010-10-22
US201161484749P 2011-05-11 2011-05-11
PCT/CH2011/000256 WO2012051734A1 (en) 2010-10-22 2011-10-24 Stable and soluble antibodies

Publications (2)

Publication Number Publication Date
PH12013500675A1 PH12013500675A1 (en:Method) 2013-06-10
PH12013500675B1 true PH12013500675B1 (en) 2017-09-06

Family

ID=44897558

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2013/500675A PH12013500675B1 (en) 2010-10-22 2011-10-24 Stable and soluble antibodies

Country Status (21)

Country Link
US (3) US8545849B2 (en:Method)
EP (2) EP3336105B1 (en:Method)
JP (4) JP6245985B2 (en:Method)
KR (4) KR20160083970A (en:Method)
CN (2) CN103154033B (en:Method)
AR (1) AR083495A1 (en:Method)
AU (1) AU2011318179B2 (en:Method)
BR (1) BR112013010949B1 (en:Method)
CA (1) CA2814766C (en:Method)
CL (2) CL2013001089A1 (en:Method)
CO (1) CO6741152A2 (en:Method)
CY (1) CY1119941T1 (en:Method)
MX (2) MX351499B (en:Method)
PH (1) PH12013500675B1 (en:Method)
PL (1) PL2630159T3 (en:Method)
RU (2) RU2558298C2 (en:Method)
TW (3) TWI652068B (en:Method)
UA (1) UA111340C2 (en:Method)
UY (1) UY33679A (en:Method)
WO (1) WO2012051734A1 (en:Method)
ZA (1) ZA201302537B (en:Method)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3628686B1 (en) * 2008-06-25 2021-07-21 Novartis AG Humanization of rabbit antibodies using a universal antibody framework
UY33679A (es) * 2010-10-22 2012-03-30 Esbatech Anticuerpos estables y solubles
AU2012325232B2 (en) * 2011-10-20 2017-08-31 Esbatech - A Novartis Company Llc Stable multiple antigen-binding antibody
EP2809344B1 (en) 2012-02-02 2016-08-24 ESBATech - a Novartis Company LLC Antibody-containing sustained-release formulation for ocular administration
EP3539563A1 (en) 2012-07-19 2019-09-18 Redwood Bioscience, Inc. Antibody specific for cd22 and methods of use thereof
US20140186350A1 (en) 2012-12-18 2014-07-03 Novartis Ag Compositions and methods for long acting molecules
EP3160991A2 (en) 2014-06-25 2017-05-03 Novartis AG Compositions and methods for long acting proteins
WO2015198243A2 (en) 2014-06-25 2015-12-30 Novartis Ag Compositions and methods for long acting proteins
CA2964786C (en) 2014-10-23 2023-10-17 Amgen Inc. Reducing the viscosity of pharmaceutical formulations with n-acetyl amino acids
SG11201803009VA (en) 2015-11-02 2018-05-30 Five Prime Therapeutics Inc Cd80 extracellular domain polypeptides and their use in cancer treatment
AU2016354009B2 (en) 2015-11-09 2021-05-20 R.P. Scherer Technologies, Llc Anti-CD22 antibody-maytansine conjugates and methods of use thereof
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
WO2017221128A1 (en) 2016-06-20 2017-12-28 Novartis Ag Methods of treating dry eye disease using tnf alpha antagonists
SG10201912565QA (en) 2016-09-29 2020-02-27 Amgen Inc Low-viscosity antigen binding proteins and methods of making them
EP3997124A4 (en) * 2019-07-09 2024-01-03 National Institute for Biotechnology in the Negev Ltd. ANTIBODIES WITH REDUCED IMMUNOGENICITY
CN112786101B (zh) * 2019-11-07 2024-11-12 中国农业大学 热稳定性抗体的制备方法
US20230046834A1 (en) * 2019-11-21 2023-02-16 Brown University Bispecific antibodies against chi3l1 and ctla4 with enhanced cytotoxic effects on tumor cells

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
EP0832981A1 (en) 1987-02-17 1998-04-01 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
DE3856559T2 (de) 1987-05-21 2004-04-29 Micromet Ag Multifunktionelle Proteine mit vorbestimmter Zielsetzung
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5147638A (en) 1988-12-30 1992-09-15 Oklahoma Medical Research Foundation Inhibition of tumor growth by blockade of the protein C system
US5644034A (en) 1989-08-07 1997-07-01 Peptide Technology Ltd. Tumour necrosis factor binding ligands
US20030225254A1 (en) 1989-08-07 2003-12-04 Rathjen Deborah Ann Tumour necrosis factor binding ligands
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
IL101147A (en) 1991-03-07 2004-06-20 Gen Hospital Corp Redirection of cellular immunity by receptor chimeras
AU675916B2 (en) 1991-06-14 1997-02-27 Genentech Inc. Method for making humanized antibodies
US5213656A (en) 1991-12-04 1993-05-25 Gerber Scientific Products, Inc. Method of using a web for etching of a surface
KR100372119B1 (ko) * 1992-07-13 2003-06-28 유카리언, 인코포레이티드 지질화된단백질을경혈관적및세포내로전달하는방법
EP0627932B1 (en) 1992-11-04 2002-05-08 City Of Hope Antibody construct
ATE204299T1 (de) 1993-03-05 2001-09-15 Bayer Ag Humane monoklonale anti-tnf alpha antikörper
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
ATE207366T1 (de) 1993-12-24 2001-11-15 Merck Patent Gmbh Immunokonjugate
DE4425115A1 (de) * 1994-07-15 1996-01-18 Boehringer Mannheim Gmbh Verfahren zur Modifizierung der Stabilität von Antikörpern
ATE219517T1 (de) 1995-08-18 2002-07-15 Morphosys Ag Protein-/(poly)peptidbibliotheken
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
HU230048B1 (hu) 1996-02-09 2015-06-29 Abbvie Biotechnology Ltd Humán TNFalfa-kötő antitestek alkalmazása
JP2000516452A (ja) * 1996-07-16 2000-12-12 プリュックテュン，アンドレアス 可溶性が増大した免疫グロブリンスーパーファミリードメインおよびフラグメント
US6470213B1 (en) 1999-03-30 2002-10-22 Kenneth A. Alley Implantable medical device
CA2396534C (en) 1999-12-28 2012-10-02 Esbatech Ag Intrabodies with defined framework that is stable in a reducing environment and applications thereof
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
WO2002002781A1 (en) 2000-06-30 2002-01-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Heterodimeric fusion proteins
SG97908A1 (en) 2000-08-03 2003-08-20 Inst Data Storage A method and apparatus for load/unload testing of disk drives
EP1332209B1 (en) 2000-09-08 2009-11-11 Universität Zürich Collections of repeat proteins comprising repeat modules
US6506412B2 (en) * 2000-11-29 2003-01-14 Sciencebased Health Treatment of dry eye syndrome
CA2817619A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
WO2003097697A2 (en) 2002-05-22 2003-11-27 Esbatech Ag Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
WO2004016740A2 (en) 2002-08-15 2004-02-26 Epitomics, Inc. Humanized rabbit antibodies
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
CA2523124A1 (en) 2003-03-20 2004-10-07 Gary D. Niehaus Self-contained assay device for rapid detection of biohazardous agents
DE10314412A1 (de) 2003-03-28 2004-10-14 Genovac Ag Genetische Immunisierung mit multiplen Expressionskonstrukten zur Herstellung von monoklonalen Antikörpern
US20050048578A1 (en) 2003-06-26 2005-03-03 Epitomics, Inc. Methods of screening for monoclonal antibodies with desirable activity
CA2533830A1 (en) 2003-08-07 2005-02-24 Epitomics, Inc. Methods for humanizing rabbit monoclonal antibodies
JP2007528723A (ja) 2003-08-22 2007-10-18 メディミューン，インコーポレーテッド 抗体のヒト化
US7462697B2 (en) 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
US20080003617A1 (en) 2004-12-20 2008-01-03 Xiaomin Fan Methods for the identification and the isolation of epitope specific antibodies
US7431927B2 (en) 2005-03-24 2008-10-07 Epitomics, Inc. TNFα-neutralizing antibodies
PT2390267E (pt) 2005-06-07 2013-07-16 Esbatech A Novartis Co Llc Anticorpos estáveis e solúveis que inibem tnf(alfa)
CN101948541B (zh) 2005-06-20 2014-08-06 健泰科生物技术公司 用于肿瘤诊断和治疗的组合物和方法
US7429487B2 (en) 2005-07-05 2008-09-30 Epitomics, Inc. Fusion partner for production of monoclonal rabbit antibodies
GB0520436D0 (en) 2005-10-07 2005-11-16 Photobiotics Ltd Biological materials and uses thereof
CA2625222A1 (en) 2005-10-11 2007-04-19 Domantis Limited Antibody polypeptide library screening and selected antibody polypeptides
UA92504C2 (en) 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
WO2007109254A2 (en) 2006-03-17 2007-09-27 Biogen Idec Ma Inc. Stabilized polypeptide compositions
DK2013236T3 (en) 2006-04-28 2015-09-21 Delenex Therapeutics Ag ANTIBODIES WHICH BIND TO the extracellular domain of the receptor ALK
US8524865B2 (en) 2006-05-30 2013-09-03 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
WO2008004834A1 (en) 2006-07-06 2008-01-10 Isu Abxis Co., Ltd Humanized monoclonal antibody highly binding to epidermal growth factor receptor, egf receptor
ES2603399T3 (es) 2006-07-10 2017-02-27 Esbatech, An Alcon Biomedical Research Unit Llc Anticuerpos scFv que atraviesan capas epiteliales y/o endoteliales
ES2442258T3 (es) 2006-10-27 2014-02-10 Abbvie Biotechnology Ltd Anticuerpos cristalinos anti-hTNF alfa
EP2089059A2 (en) 2006-11-10 2009-08-19 Genentech, Inc. Method for treating age-related macular degeneration
EP3202786A3 (en) 2007-03-12 2017-10-11 ESBATech, an Alcon Biomedical Research Unit LLC Sequence based engineering and optimization of single chain antibodies
TWI501976B (zh) 2007-05-21 2015-10-01 Alder Biopharmaceuticals Inc 抗ＴＮＦ－α之抗體及其用途
DK2158315T3 (en) * 2007-06-25 2016-06-06 Esbatech Alcon Biomed Res Unit Methods of modifying antibodies and modified antibodies with improved functional properties
KR101530723B1 (ko) 2007-06-25 2015-06-22 에스바테크 - 어 노바티스 컴파니 엘엘씨 단일 쇄 항체의 서열에 기초한 공학처리 및 최적화
WO2009052140A1 (en) * 2007-10-15 2009-04-23 Alcon Research, Ltd. Use of tnf receptor antagonists for treating dry eye
US8399627B2 (en) * 2007-12-31 2013-03-19 Bayer Pharma AG Antibodies to TNFα
RU2567100C2 (ru) * 2008-06-25 2015-10-27 ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи СТАБИЛЬНЫЕ И РАСТВОРИМЫЕ АНТИТЕЛА, ИНГИБИРУЮЩИЕ TNFα
LT3241843T (lt) 2008-06-25 2021-09-27 Novartis Ag Imuninių rišiklių tirpumo optimizavimas
EP3628686B1 (en) 2008-06-25 2021-07-21 Novartis AG Humanization of rabbit antibodies using a universal antibody framework
SI2307454T1 (sl) 2008-06-25 2017-05-31 ESBA Tech, an Alcon Biomedical Research Unit LLC Stabilna in topna protitelesa, ki inhibirajo VEGF
MX2011000006A (es) 2008-06-30 2011-08-03 Esbatech Alcon Biomed Res Unit Polipeptidos funcionalizados.
BRPI0915460A2 (pt) 2008-07-10 2015-11-10 Esbatech Alcon Biomed Res Unit métodos e composições para a liberação intensificada de macromoléculas
EP2918602A1 (en) 2009-04-16 2015-09-16 AbbVie Biotherapeutics Inc. Anti-TNF-alpha antibodies and their uses
MX352871B (es) 2009-12-23 2017-12-13 Esbatech Alcon Biomed Res Unit Método para disminuir inmunogenicidad.
CN103096927A (zh) 2010-07-15 2013-05-08 奥列格·伊里奇·爱泼斯坦 复合药物组合物以及治疗胃肠道功能性疾病或病症的方法
UY33679A (es) * 2010-10-22 2012-03-30 Esbatech Anticuerpos estables y solubles
UY33702A (es) 2010-11-02 2012-05-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
AR084210A1 (es) 2010-12-08 2013-05-02 Abbott Lab PROTEINAS DE UNION AL TNF-a
GB201112429D0 (en) 2011-07-19 2011-08-31 Glaxo Group Ltd Antigen-binding proteins with increased FcRn binding
MX2014004980A (es) 2011-10-24 2014-09-11 Abbvie Inc Inmunoaglutinantes biespecificos dirigidos contra tnf e il-17.
RU2014120755A (ru) 2011-10-24 2015-12-10 Эббви Инк. Иммуносвязующие агенты, направленные против tnf

Also Published As

Publication number Publication date
EP2630159B1 (en) 2017-11-22
AU2011318179A1 (en) 2013-05-02
JP7148228B2 (ja) 2022-10-05
CA2814766A1 (en) 2012-04-26
KR101635917B1 (ko) 2016-07-04
CA2814766C (en) 2017-11-28
RU2013123266A (ru) 2014-11-27
CL2013001089A1 (es) 2014-03-07
US20120100153A1 (en) 2012-04-26
UY33679A (es) 2012-03-30
JP2013544078A (ja) 2013-12-12
BR112013010949B1 (pt) 2022-02-01
CN108359012B (zh) 2021-12-24
EP3336105B1 (en) 2020-11-04
KR20190016137A (ko) 2019-02-15
MX2013004295A (es) 2013-06-05
CL2015002735A1 (es) 2016-03-04
CN103154033B (zh) 2018-04-24
AU2011318179B2 (en) 2014-12-11
KR20130138806A (ko) 2013-12-19
BR112013010949A2 (en:Method) 2017-09-05
PL2630159T3 (pl) 2018-04-30
JP6245985B2 (ja) 2017-12-13
US20130344086A1 (en) 2013-12-26
JP2019054814A (ja) 2019-04-11
PH12013500675A1 (en:Method) 2013-06-10
TWI702230B (zh) 2020-08-21
AR083495A1 (es) 2013-02-27
EP3336105A1 (en) 2018-06-20
WO2012051734A1 (en) 2012-04-26
TW201920270A (zh) 2019-06-01
RU2015119440A (ru) 2015-11-27
TW201221142A (en) 2012-06-01
CO6741152A2 (es) 2013-08-30
US8545849B2 (en) 2013-10-01
UA111340C2 (uk) 2016-04-25
US20160176959A1 (en) 2016-06-23
TWI652068B (zh) 2019-03-01
CY1119941T1 (el) 2018-12-12
US9598487B2 (en) 2017-03-21
US10570198B2 (en) 2020-02-25
KR101947520B1 (ko) 2019-02-14
EP2630159A1 (en) 2013-08-28
TWI584816B (zh) 2017-06-01
ZA201302537B (en) 2014-06-25
RU2558298C2 (ru) 2015-07-27
KR20160083970A (ko) 2016-07-12
CN103154033A (zh) 2013-06-12
JP2015193664A (ja) 2015-11-05
CN108359012A (zh) 2018-08-03
KR20170020558A (ko) 2017-02-22
TW201630623A (zh) 2016-09-01
JP2017184770A (ja) 2017-10-12
RU2015119440A3 (en:Method) 2019-01-28
MX351499B (es) 2017-10-17

Similar Documents

Publication Publication Date Title
PH12013500675B1 (en) Stable and soluble antibodies
PH12014501962A1 (en) STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFa
MX2007015280A (es) Anticuerpos estables y solubles que inhiben tnf-alfa.
WO2019224025A3 (en) Antagonizing cd73 antibody
MX2015008446A (es) Composiciones de proteinas de union multivalentes.
MX2013003681A (es) Ácidos nucleicos manipulados y métodos de uso de los mismos.
MX360403B (es) Proteinas de union a amiloide beta.
PH12013500933A1 (en) Methods and compositions for neural disease immunotherapy
TN2014000148A1 (en) Antigen binding protein and its use as addressing product for the treatment of cancer
WO2012009544A3 (en) Domain insertion immunoglobulin
TN2011000528A1 (en) Compositions and methods for antibodies targeting complement protein c3b
IN2014CN03936A (en:Method)
PH12014501970A1 (en) Antibodies to bradykinin b1 receptor ligands
MX2011012039A (es) Anticuerpos bloqueadores anti-dkk-1 y sus usos.
MX2013003470A (es) Estructuras de consenso de antigenos y vacunas elaboradas a partir de estas y metodos para utilizarlas en el tratamiento de la malaria.
MX366622B (es) Composicion farmaceutica estable de la proteina de fusion tnfr:fc.
WO2011116212A3 (en) Bone morphogenetic protein receptor binding agents and methods of their use
WO2011046832A3 (en) Granulysin in immunotherapy
WO2013162905A8 (en) Methods of producing and using regulatory b-cells
CA2819463C (en) Tomm34 peptides and vaccines including the same
MY176703A (en) Stable and soluble antibodies inhibiting tnf()
MY164890A (en) Stable and soluble antibodies inhibiting tnfa
MY176238A (en) Stable and soluble antibodies inhibiting tnf()
MX342638B (es) Anticuerpos estables y solubles que inhiben tnf-alfa.
PL391384A1 (pl) Kompleks rybosomalnych białek P z zarodźca malarii Plasmodium falciparum jako antygen patogenu malarii oraz sposób otrzymania tego antygenu i kaseta ekspresyjna, zwłaszcza do tego sposobu